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OBJECTIVE—The pathogenesis of autoimmune pancreatitis
(AIP) and fulminant type 1 diabetes remains unclear, although it
is known that immune-mediated processes severely compromise
the endocrine and exocrine functions in both diseases.
RESEARCH DESIGN AND METHODS—We have screened a
TriplEx2 human pancreas cDNA library with serum from a
patient with AIP and obtained positive clones. Sequence analysis
revealed that 7 of 10 clones were identical to human amylase
-2A. Using a recombinant COOH-terminal amylase -2A protein,
we developed an enzyme-linked immunosorbent assay system to
detect autoantibodies against human amylase -2A.
RESULTS—All 15 serum samples from patients with AIP recog-
nized the recombinant protein, whereas sera from 25 patients
with chronic alcoholic pancreatitis and sera from 25 patients
with a pancreas tumor did not. Interestingly, 88% (15/17) of
patients with fulminant type 1 diabetes were positive for an
autoantibody against amylase -2A. These antibodies were de-
tected in 21% of patients with acute-onset type 1 diabetes (9 of
42) and 6% of type 2 diabetic patients (4 of 67).
CONCLUSIONS—These results suggest that an autoantibody
against amylase -2A is a novel diagnostic marker for both AIP
and fulminant type 1 diabetes and that, clinically and immuno-
logically, AIP and fulminant type 1 diabetes are closely related.
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R
ecently, autoimmune pancreatitis (AIP), a
unique form of chronic pancreatitis, has been
reported as a discrete disease entity (1). It is
characterized by 1) irregular narrowing of the
main pancreatic duct and swelling of the pancreas, both of
which are due to abundant lymphoplasmacytic inﬂamma-
tion to the exocrine pancreas (2); 2) the increased serum
level of IgG and IgG4; 3) positive autoantibodies such as
lactoferrin autoantibody or carbonic anhydrase II (CAII)
autoantibody (3,4); and 4) a high prevalence of diabetes
with complications (5).
We recently reported that a high proportion of pancre-
atic islets and exocrine pancreatic tissues were inﬁltrated
by CD4
 or CD8
 T-cells in the inﬂammatory process,
which might induce diabetes in AIP (6). In addition,
treatment with prednisolone improved insulin secretion
and glycemic control in AIP patients (5). These data
support the concept that autoimmune mechanism(s) plays
a pivotal role in the destruction of the endocrine and
exocrine pancreas in AIP patients with diabetes.
Clinically, the most common initial symptom of AIP is
jaundice, but in some patients, no symptoms or only mild
symptoms, frequently without acute attacks of pancreati-
tis, may be present (7). It is difﬁcult to distinguish AIP from
other types of chronic pancreatitis or cancer of the pan-
creatic head (8). In such cases, detection of autoantibodies
is useful for diagnosing AIP, but a proportion of patients
with AIP are negative for autoantibodies against lactofer-
rin and CAII (3,4).
We encountered an AIP patient whose serum IgG and
IgG4 levels were 3,498 and 2,430 mg/dl, respectively. It has
been reported that median levels (5th and 95th percen-
tiles) of IgG and IgG4 from patients with AIP were 2,389
mg/dl (1,349 and 4,310) and 742 mg/dl (265 and 1,150),
respectively (3), so high concentrations of IgG in this case
prompted us to search for new autoantigens associated
with AIP. We also searched for the presence or absence of
new autoantibodies in patients with abrupt onset and
severe ketoacidosis-prone type 1 diabetes [called fulmi-
nant type 1 diabetes (9,10)], which involve the exocrine
pancreas and the endocrine pancreas.
RESEARCH DESIGN AND METHODS
Serum used for screening the human pancreas cDNA library was obtained
from a 67-year-old male patient (A.O.), who was admitted to our hospital
complaining of slight abdominal pain and jaundice. Computed tomography
revealed an enlarged pancreas, and laboratory ﬁndings showed high concen-
trations of IgG and IgG4. Tests for anti-lactoferrin and anti-CAII antibodies
were both positive, but those for anti-nuclear antibody, anti-mitochondrial
antibody, and rheumatoid factor were negative.
Additional AIP sera were obtained from 14 newly diagnosed patients at the
University of Yamanashi Hospital and Toranomon Hospital, Tokyo. Diagnosis
of AIP was based on criteria proposed by the Japan Pancreas Society (11). Our
15 patients ﬁlled criterion 1 (narrowing of the main pancreatic duct or
enlargement of pancreas by imaging studies), together with criterion 2 (high
serum -globulin, IgG, or IgG4 or the presence of autoantibodies, such as
anti-nuclear antibodies and rheumatoid factor) and/or criterion 3 (marked
interlobular ﬁbrosis and prominent inﬁltration of lymphocytes and plasma
cells in the periductal area). Serum samples were taken from 25 patients with
chronic alcoholic pancreatitis, who were diagnosed according to a history of
alcohol abuse, impaired exocrine pancreatic function, and the presence of
calciﬁed precipitates in the pancreas by imaging studies [Japan Pancreas
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732 DIABETES, VOL. 58, MARCH 2009Society, criteria for chronic pancreatitis 2001 (12)]. Twenty-ﬁve serum sam-
ples were recruited from patients with pancreas tumor (cancer [n  8] and
intraductal papillary mucinous tumor [IPMT, n  17]). Fulminant type 1
diabetes (n  17, 13 cases at the onset and 4 cases after onset) was diagnosed
by criteria (fasting C-peptide 0.033 nmol/l and A1C 8.0% or C-peptide
0.540 nmol/l and A1C 8.0%) as reported previously (13,14). Fulminant type
1 diabetes associated with pregnancy (15) was excluded from the present
study. Acute-onset type 1 diabetes (n  42) (12) and type 2 diabetes (n  67)
samples were also recruited. The patients’ clinical characteristics are summa-
rized in Table 1. Serum from patients with Hashimoto’s thyroiditis (n  47)
were also studied. Diagnosis of the disease was made by elastic goiter and
autoantibodies against both thyroglobulin and thyroid peroxidase. Control
sera were obtained from 100 (59 male and 41 female) healthy volunteers.
Immunoscreening. The TriplEx2 human pancreas large insert cDNA library
(HL5517u) and Escherichia coli XL-1 competent cells were obtained from BD
Biosciences Clontech (Palo Alto, CA). The plaques on the plate were trans-
ferred to nitrocellulose ﬁlters presoaked with 10 mmol/l isopropyl--D-thioga-
lactopyranoside (IPTG), washed with Tris-buffered saline (TBS) containing
0.05% Tween 20 (TBST), and blocked with TBST containing 1% BSA. The
ﬁlters were incubated overnight at 4°C with the sera from the patient with AIP
(A.O.) at a dilution of 1:500. After washing four times with TBST, the ﬁlters
then reacted with goat horseradish peroxidase–conjugated anti-human IgG
(American Qualex, San Clemente, CA) at a dilution of 1:2,000 for 30 min at
room temperature. The ﬁlters were also washed four times with TBST;
positive reaction was detected with 3,3-diaminobenzidine.
Preparation of the recombinant human AMY-2A. A cDNA fragment of the
positive clone was ampliﬁed by PCR with the sense primer, 5-ATGGGGATC
CTTGGGGTTTCGTACCTTCTGACAGA, and antisense primer, 5-CTTCGAAT
TCCCAATTTAGATTCAGCATGAATTGC. The PCR product was digested with
BamHI and EcoRI and then ligated into pTrc His B (Invitrogen, Carlsbad, CA).
After sequencing, the plasmid was transfected into E. coli BL-21 (Novagen,
Darmstadt, Germany). The production of the recombinant protein was in-
ducted with 1 mmol/l IPTG and puriﬁed by His Bond column chromatography.
Western blot analysis. The 0.1% SDS–15% PAGE and transferring onto the
nitrocellulose membrane was carried out as previously described (16) with
slight modiﬁcations as follows: The membrane was blocked with 5% skim milk
and 5% goat serum in TBS and then incubated with sera from the patients with
AIP (1:500) overnight at 4°C. After washing ﬁve times with TBST, the
membrane was reacted with goat horseradish peroxidase–conjugated anti-
human IgG (1:2,000) for 30 min at room temperature. Positive reaction was
detected by the same way as described in IMMUNOSCREENING.
In vitro translation and immunoprecipitation. A cDNA fragment of
AMY-2A was ampliﬁed by PCR with the sense primer, 5-ATGGGGATCCATG
TGGGGTTTCGTACCTTCTGACAGA, and antisense primer, 5-CTTCGAATTC
CCAATTTAGATTCAGCATGAATTGC, which added an ATG codon at the
NH2-terminus. The PCR product was digested with BamHI and EcoRI and then
ligated into pcDNA3.1.
35S-labeled human AMY-2A was prepared with
PROTEIN script II (Ambion, Austin, TX) and [
35S]methionine (GE Healthcare,
Piscataway, NJ).
35S–AMY-2A was incubated with patients’ sera (100) or
anti-human amylase antibody (100; sc-12821; Santa Cruz Biotechnology,
Santa Cruz, CA) in 200 	l PBS containing 1% BSA at 4°C overnight, with 10 	l
GammaBind G Sepharose (GE Healthcare) added. After further incubation at
room temperature for 60 min, the mixtures were centrifuged at 10,000 rpm for
5 min. The pellets were washed three times with PBS containing 0.05% Tween
20 (PBST). Final pellets were directly counted or dissolved with 10 mmol/l
Tris-HCl (pH. 6.8) containing 0.1% SDS, boiled for 3 min, and loaded onto a
0.1% SDS–15% polyacrylamide gel.
Enzyme-linked immunosorbent assay for detecting autoantibody
against human AMY-2A. Autoantibody against human AMY-2A was mea-
sured by enzyme-linked immunosorbent assay (ELISA) using methods previ-
ously described (5). In brief, a microtiter plate (Coster 3590; Corning,
Horseheads, NY) was coated with 50 	l 0.1 	g recombinant human AMY-2A
overnight at 4°C. After washing the plate three times with PBST, the plate was
incubated with 200 	l 1% BSA in PBS for 30 min. Next, the patients’ sera were
tested in triplicate at dilutions of 1:200 in 1% BSA for 1 h. The bound antibody
was specially reacted with goat horseradish peroxidase–conjugated anti-
human IgG (1:2,000) in 1% BSA for 30 min at room temperature. After washing,
the plate was incubated with 100 	l 1-Step Slow TMB-ELISA (Pierce,
Rockford, IL) for 30 min. The reaction was terminated by adding 100 	l 1 mol/l
H2SO4, and absorbance was determined at an optical density of 450 nm. Intra-
and interassay coefﬁcient of variation, determined with the same lot of ﬁve
ELISA plates, were 4.28 and 7.72%, respectively.
Ethics. An ethical committee approved all study protocols, and patients gave
informed consent.
Statistical analysis. Statistical analysis was carried out using Fisher’s exact
test (JMP, Cary, NC), in which we considered statistically signiﬁcant if P
values were 
0.05. Receiver operating characteristic (ROC) analysis was
carried out with MedCalc (MedCalc Software, Mariakerke, Belgium).
RESULTS
Cloning of cDNAs from human pancreas. We com-
pletely screened 2  10
4 plaques with the AIP patient’s
serum (A.O.) and obtained 10 positive clones. Nucleotide
sequencing of the insert cDNAs and a subsequent homol-
ogy search revealed that 7 of 10 clones were identical to
human amylase-2A (AMY-2A). When compared with the
nucleotide sequence of the human AMY-2A cloned by Wise
et al. (17), four of seven clones contained the full coding
sequence, whereas the 5 ends of the other three clones
started from 61, 799, and 897 bp (A in ATG is designated as
1) (Fig. 1). Other nonamylase clones were those of the
housekeeping genes, such as the heat shock protein and
the nuclear protein.
TABLE 1
Clinical characteristics of subjects
Type of diabetes n
Age
(years)
Sex
(male/female)
Duration of
diabetes
(months)*
Treatment
by insulin*
Autoimmune pancreatitis 15 66 (58–75) 14/1 — 8
Before PSL 12
After PSL 3
Chronic alcoholic pancreatitis 25 63 (53–70) 18/7 — 10
Pancreatic tumor 25 71 (63–73) 12/13 — 8
Cancer 8
IPMT 17
Fulminant type 1 diabetes 17 40 (28–53) 14/3 17
At onset† 13 0.76  0.20
After onset 4 13.5  2.38
Acute-onset type 1 diabetes 42 25 (23–33) 14/28 29.0  45.0 42
At onset† 22 0.7  0.9
After onset 20 51.0  50.0
Type 2 diabetes 67 62 (58–65) 43/24 130  91.0 37
Hashimoto’s thyroiditis 47 60 (55–62) 6/41 — —
Control subjects 100 47 (40–48) 59/41 — —
Data are medians (95% CI) or means  SD. PSL, prednisolone; IPMT, intraductal papillary mucinous tumor. *Duration from the onset of
diabetes to the time of sample collection. †At onset; within 3 months after onset.
T. ENDO AND ASSOCIATES
DIABETES, VOL. 58, MARCH 2009 733Western blot analysis, immunoprecipitation, and
ELISA system for detecting anti-human AMY-2A.
Because IgG from the AIP patient used for screening
recognized four different lengths of human AMY-2A
clones, we hypothesized that the regions shared by these
four clones, from codons 299 to 512, might contain a
common epitope for the patient’s IgG (Fig. 1). Therefore,
we produced histidine-tagged human AMY-2A from codons
299 to 512 (AMY-2A/299–512) in E. coli BL21 and carried
out Western blot analysis (Fig. 2A). Patient’s serum (A.O.)
recognized the 30-kDa recombinant protein (line 1), but
sera from healthy volunteers did not (lines 3 and 4). When
the patient’s serum was preincubated with the recombi-
nant protein, positive staining was abolished (line 2),
suggesting that the autoantibody reacted with the recom-
binant protein, which contains the epitope.
Anti-human AMY-2A antibody produced in goat was
bound to the in vitro–translated
35S–AMY-2A and was
precipitated by protein G–sepharose (Fig. 2B). IgG from
two patients with AIP also bound to the labeled protein
and was precipitated, but the IgG from two healthy
volunteers did not (Fig. 2B). This recombinant ﬂuid phase
autoantibody assay with in vitro transcription and trans-
lation of AMY-2A without additional amino acids, such as
His-Tag, conﬁrmed the speciﬁcity of the autoantibody
against the protein.
Next, by coating the protein onto the plate, we devel-
oped an ELISA system for detecting anti-amylase antibod-
ies in the serum. When compared with the normal serum,
patient sera showed strong signals, which were well
correlated with immunoprecipitated
35S–AMY-2A by pro-
tein G–sepharose (Fig. 2C). This positive reaction in ELISA
was displaced in a concentration-dependent fashion by
AMY-2A/299–512 (Fig. 2D). When the AIP patient’s serum
(A.O.) was diluted, we could detect positive signals up to
1,000 dilution (Fig. 2E). To obtain a cutoff value for
positivity, we carried out ROC analysis of the healthy
FIG. 1. Cloning of human amylase -2A cDNAs from TriplEx2 human
pancreas cDNA library. Seven clones of human amylase -2A cDNAs.
Their lengths and 5-ends are shown (A in ATG is designated as 1). The
top bar indicates human amylase -2A cDNA as reported by Wise et al.
(17), and the common regions shared by all seven clones, from codons
299 to 512, are shown in the bottom bar.
FIG. 2. Western blot analysis and ELISA for detecting anti-human AMY-2A. A: Western blot analysis. Recombinant human AMY-2A (50 ng) from
codons 299 to 512 (AMY-2A/299–512) was electrophoresed in 0.1% SDS–15% polyacrylamide and transferred onto a nitrocellulose ﬁlter. The
ﬁlters reacted with serum (1,000) from an AIP patient (line 1) and normal control sera (lines 3 and 4). Line 2, AIP patient’s serum preincubated
with 1 g/ml AMY-2A/299–512. MW, molecular weight markers. B: Immunoprecipitation of
35S–AMY-2A with antibodies.
35S–AMY-2A was
incubated with goat anti-amylase (line 1), normal goat IgG (line 2), sera from AIP patients (lines 3 and 4), and sera from healthy volunteers (lines
5 and 6) and then precipitated with protein G–sepharose. The pellets were electrophoresed in 0.1% SDS–15% polyacrylamide and analyzed with
Bas 2000 image analyzer (Fujix, Tokyo). C: Correlation between the result of ELISA and that of immunoprecipitation. By coating the recombinant
human AMY-2A/299–512, we developed an ELISA system for detecting anti-human AMY-2A. Sera from 11 patients with AIP (F) and two normal
control subjects (E) were assayed by ELISA and immunoprecipitation for detecting the autoantibody. D: Absorption of positive ELISA signal with
recombinant AMY-2A. One milliliter of a patient’s serum (1:500) was preincubated with the recombinant protein at the indicated dose overnight
at 4°C, and then the serum was used as the ﬁrst antibody. The data are the mean of triplicate values. OD, optical density. E: Serum dilution
experiment in ELISA assay. Positive serum from patient A.O. was diluted as indicated, and ELISA assay was carried out. The data are the mean
of triplicate values. F: ROC analysis of the healthy volunteers and fulminant type 1 diabetic patients. We carried out ROC analysis of the healthy
volunteers (n  100) and fulminant type 1 diabetic patients (n  17) with MedCalc.
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tients (n  17) (Fig. 2F). Table 2 shows criterion values
and coordinates of the ROC curve. When the value was set
as 34 (area under the ROC curve 0.92; signiﬁcance level
P  0.0001), sensitivity, speciﬁcity, and positive predictive
value were 88.24, 99.0, and 93.7%, respectively.
Prevalence of autoantibody against human AMY-2A
in AIP patients. Using the ELISA system, we determined
the prevalence of autoantibody against human AMY-2A in
AIP patients and various pancreatic diseases (Fig. 3). All
15 IgGs from patients with AIP were positive for AMY-2A/
299–512, whereas 1 of 100 IgGs from control subjects was
positive for the antibody (P 
 0.001, Fisher’s exact test).
All the IgGs from the patients with chronic alcoholic
pancreatitis (n  25) or with pancreas tumor (pancreatic
cancer, n  8; IPMT, n  17) were negative for the antigen.
Antibodies were detected in 9% (4/47) of patients with
Hashimoto’s thyroiditis, a representative organ-speciﬁc
autoimmune disease (Fig. 3A).
Figure 3B shows the time course of the autoantibody
titer from two AIP patients before and after prednisolone
treatment. In patient A.O., IgG4 gradually increased and
reached 5,540 mg/dl, but administration of prednisolone
initiated a rapid decrease of IgG4 to 571 mg/dl. Before
prednisolone treatment, the titer of the autoantibody
against AMY remained high, and prednisolone treatment
induced a rapid decrease of the titer of AMY-2A autoanti-
body to a normal level. The fall rate of the antibody titer
seemed to be parallel to that of serum IgG4. In patient
T.M., administration of prednisolone also rapidly de-
creased the titer of the autoantibody against AMY. The
autoantibodies did not increase even at the drug mainte-
nance dose in both cases.
Prevalence of autoantibody against human AMY-2A
in patients with fulminant type 1 diabetes and acute-
onset type 1 diabetes. We next studied the prevalence of
autoantibody against human AMY-2A in various types of
diabetic patients (fulminant type 1 diabetes, n  17;
acute-onset type 1 diabetes, n  42; and type 2 diabetes,
n  67; Fig. 4). Interestingly, 88% of patients with fulmi-
nant type 1 diabetes were positive for the autoantibody,
but 1% of control was positive for the antibody (P 
 0.001,
Fisher’s exact test). The autoantibody was detected with
low frequency in patients with acute-onset type 1 diabetes
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FIG. 3. Prevalence of autoantibody against human AMY-2A in patients with various pancreatic diseases. A: Prevalence of autoantibody against
human AMY-2A in patients with AIP (n  15), chronic alcoholic pancreatitis (CP, n  25), pancreatic tumor (PT, n  25), control subjects from
healthy volunteers (C, n  100), and Hashimoto’s thyroiditis (H, n  47) was examined by ELISA, as described in RESEARCH DESIGN AND METHODS.
The data are the mean of triplicate values. The dotted line shows a cutoff value. Fisher’s exact test was carried out between AIP and control
groups. *P < 0.001. B: Time course of anti-AMY antibody and IgG4 of AIP patients. AIP patient (A.O.), whose IgG was used to screen TriplEx2
human pancreas cDNA library, was treated with prednisolone (arrow). Before and after the treatment, anti-AMY antibody (F-F) and IgG4 (E-E)
were measured. In the other AIP patient (T.M.), titer of the anti-AMY antibody (Œ-Œ) was also measured before and after prednisolone treatment
(arrow).
TABLE 2
Criterion values and coordinates of the ROC curve
Criterion Sensitivity (%) Speciﬁcity (%)
Positive predictive
value
Negative predictive
value
3.2 100.00 (80.3–100.0) 0.00 (0.0–3.7) 14.5
11.4 100.00 (80.3–100.0) 9.00 (4.2–16.4) 15.7 100
11.8 94.12 (71.2–99.0) 9.00 (4.2–16.4) 15.0 90.0
17.3 94.12 (71.2–99.0) 53.00 (42.8–63.1) 25.4 98.1
17.5 88.24 (63.5–98.2) 55.00 (44.7–65.0) 25.0 96.5
34.0* 88.24 (63.5–98.2) 99.00 (94.5–99.8) 93.7 98.0
34.7 82.35 (56.6–96.0) 99.00 (94.5–99.8) 93.3 97.1
35.2 82.35 (56.6–96.0) 100.0 (96.3–100.0) 100.0 97.1
98.4 0.00 (0.0–19.7) 100.0 (96.3–100.0) 85.5
Data in parentheses are 95% CI. *Cutoff value for positivity.
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of 67).
DISCUSSION
In 2002, Barera et al. (18) reported a case of an 11-year-old
girl with celiac disease and hypothyroidism. Because of
hyperamylasemia, she was suspected to have chronic
pancreatitis, but no pancreatic damage was demonstrated.
By using ELISA to detect autoantibodies to amylase, they
found that she produced an autoantibody against porcine
amylase and that this declined after the institution of a
gluten-free diet. In the present study, we also detected an
autoantibody against pancreas-speciﬁc AMY-2A in all of
the AIP patients, but not in patients with chronic alcoholic
pancreatitis and with pancreatic tumors.
The presence of autoantibodies against CAII, lactofer-
rin, and pancreatic secretory trypsin inhibitor (PSTI) has
been reported (3,4,19). However, the distribution of these
molecules is non–organ speciﬁc (20–22), and the preva-
lence of these autoantibodies against CAII, lactoferrin, and
PSTI in AIP is rather low, ranging from 42
73% (3,4,19).
Using 13 serum samples from our AIP patients, we carried
out ELISA assays for autoantibodies against CAII and
lactoferrin. As a result, 66% (10 of 15) were positive for
CAII, and 53% (8 of 15) were positive for lactoferrin. Thus,
an autoantibody against AMY-2A might be a more sensitive
marker for AIP than that of CAII, lactoferrin, or PSTI.
Furthermore, the adoptive transfer of amylase-speciﬁc
CD4
 T-cells to rats was able to confer pancreatitis,
whereas the transfer experiment with lactoferrin-speciﬁc
or CAII-speciﬁc CD4
 T-cells failed to induce experimen-
tal pancreatitis (23). Our ﬁndings of a high prevalence of
autoantibody against AMY-2A in human AIP and the
results from the adoptive transfer experiment of amylase-
speciﬁc CD4
 T-cells to rodents suggest that cellular
and/or humoral autoimmunity against AMY-2A plays some
role in the pathogenesis of AIP.
Approximately 80% of patients with chronic pancreatitis
are alcoholic, the pathogenesis of which still remains
unclear. However, it is well known that acute or chronic
alcohol exposure suppresses all branches of the immune
system (24), and none of our sera from patients with
chronic alcoholic pancreatitis were positive for autoanti-
body against AMY-2A (Fig. 3). Therefore, an assay for
autoantibody against AMY-2A is useful for distinguishing
AIP from chronic alcoholic pancreatitis.
It is of particular interest that anti–AMY-2A autoanti-
body is detected in 88% of patients with fulminant type 1
diabetes. Fulminant type 1 diabetes is a recently proposed
subtype of type 1B, nonimmune-mediated, or idiopathic
type 1 diabetes (9,10). A nationwide survey revealed that
fulminant diabetes accounted for 
20% of Japanese type 1
diabetes with ketosis or ketoacidosis and ﬂu-like symp-
toms frequently observed at onset (25). Clinical character-
istics of this subtype of type 1 diabetes are 1) remarkably
abrupt onset of disease; 2) very short (
1 week) duration
of diabetic symptoms; 3) severe ketoacidosis at diagnosis;
4) negative status of islet-related autoantibodies, such as
GADAb and anti–IA-2 antibody; 5) virtually no C-peptide
secretion (10 	g/day in urine); and 6) elevated serum
pancreatic enzyme levels (26). These features and the
absence of insulitis in patients’ pancreases have led some
to hypothesize that an autoimmune mechanism does not
contribute to the development of fulminant type 1 diabe-
tes, but rather that viral infection plays a central role in the
pathogenesis of the disease (27). However, we previously
demonstrated CD4
 and CD8
 T-cell inﬁltration to pan-
creatic exocrine cells and to the islet in an autopsy case
deceased immediately after the onset of fulminant type 1
diabetes (28).
Imagawa and Hanafusa (27) also conﬁrmed cellular
inﬁltration of pancreatic islets in patients with fulminant
type 1 diabetes. Shimada et al. (29) described a fulminant
type 1 diabetic patient with a high serum level of CXCL10,
a chemokine that induces migration of activated T-cells to
local lesions and GAD-reactive CD4
 cells in the periph-
ery. These results, and the presence of an autoantibody
against AMY-2A, suggest that the disease might be auto-
immune-related, involving the exocrine and the endocrine
pancreas (10,28).
Exocrine dysfunction and impaired glucose tolerance
are common features for both AIP and fulminant type 1
diabetes. With regard to the HLA genotype, Kawa et al.
(30) demonstrated that the DRB1*0405-DQB1*0401 haplo-
type is closely associated with AIP in the Japanese popu-
lation, and Tanaka et al. (31) revealed that the DQA1*0303-
DQB1*0401 haplotype is strongly associated with
fulminant type 1 diabetes in a homologous manner. When
we studied the frequency of this allele in our patients with
AIP, 5 of 15 patients were heterozygous for the
DRB1*0405-DQB1*0401 haplotype. Although further study
with larger sample sizes will be needed, these two reports
and our own analysis suggest the importance of the
DQB1*0401 allele in both diseases. Furthermore, we are
able to detect autoantibody against AMY-2A in both with
nearly the same prevalence. Although further investigation
is needed, the present results suggest that clinically and
immunologically, AIP and fulminant type 1 diabetes are
closely related to one another.
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FIG. 4. Prevalence of autoantibody against human AMY-2A in patients
with various types of diabetes. Prevalence of autoantibody against
human AMY-2A (F) in patients with fulminant type 1 diabetes
(FT1DM, n  17), acute-onset type 1 diabetes (AT1DM, n  42), type
2 diabetes (T2DM, n  67), and control subjects from healthy volun-
teers (C, n  100) was studied by ELISA, as described in RESEARCH
DESIGN AND METHODS. The data are the mean of triplicate values. The
dotted line shows a cutoff value. Fisher’s exact test was carried out
between fulminant type 1 diabetic and control groups. *P < 0.001.
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